Heart, Lung and Circulation
Original Article| Volume 29, ISSUE 10, P1440-1448, October 2020

Download started.


Medium-Term Bioresorbable Scaffold Outcomes Utilising Data From an Australian Clinical Quality Registry

Published:December 03, 2019DOI:


      Bioresorbable scaffolds (BRS) are a novel technology in coronary intervention. However, recent trials demonstrate higher rates of device failure compared to contemporary drug-eluting stents. This study sought to utilise a clinical quality registry to assess the medium-term safety of the Abbott Absorb BRS (Abbott Vascular, Santa Clara, CA, USA), in an Australian context.


      A prospective, observational study of 192 BRS percutaneous coronary interventions (PCI) compared to 31,773 non-BRS PCIs entered in the Victorian Cardiac Outcomes Registry from 2013 to 2017. The main outcome measure was patient-oriented composite endpoint (POCE) events comprising all-cause mortality, any myocardial infarction (MI), and any revascularisation.


      Bioresorbable scaffolds patients (mean age 61.6±10.5 years, 79% male) were younger, had less comorbidity, less prior PCI, fewer ST elevation myocardial infarction (STEMI) presentations, lower rates of multi-lesion disease and more adjuvant devices compared to non-BRS PCI (all p<0.01). All-cause mortality was 2.1%, myocardial infarction (MI) 2.1%, scaffold thrombosis 3.1% and any revascularisation 14.1% (mean follow-up 27.4±8.9 months). POCE events occurred in 11.5% at 1 year and 16.9% at 2 years, comparable to pooled-trial data. Multivariate predictors of POCE were >1 scaffold used (odds ratio [OR] 4.6, 95% confidence interval [CI] 1.9-11.4, p<0.01) and scaffold diameter ≤2.5 mm (OR 3.3, 95% CI 1.4–7.6, p=0.02). Over 95% guideline adherence was achieved in six of eight patient selection criteria and four of six device deployment criteria.


      In an Australian setting, BRS were used in non-complex patients. Most guidelines for use were adhered to and outcomes were comparable to pooled trial data. Clinical quality registries are effective in assessing novel treatments and technologies when potential safety concerns develop.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Heart, Lung and Circulation
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bangalore S.
        • Kumar S.
        • Fusaro M.
        • Amoroso N.
        • Attubato M.J.
        • Feit F.
        • et al.
        Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
        Circulation. 2012; 125: 2873-2891
        • Joner M.
        • Finn A.V.
        • Farb A.
        • Mont E.K.
        • Kolodgie F.D.
        • Ladich E.
        • et al.
        Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.
        J Am Coll Cardiol. 2006; 48: 193-202
        • Byrne R.A.
        • Stefanini G.G.
        • Capodanno D.
        • Onuma Y.
        • Baumbach A.
        • Escaned J.
        • et al.
        Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary.
        Eur Heart J. 2018; 39: 1591-1601
        • Ellis S.G.
        • Kereiakes D.J.
        • Metzger D.C.
        • Caputo R.P.
        • Rizik D.G.
        • Teirstein P.S.
        • et al.
        Everolimus-eluting bioresorbable scaffolds for coronary artery disease.
        N Engl J Med. 2015; 373: 1905-1915
        • Wykrzykowska J.J.
        • Kraak R.P.
        • Hofma S.H.
        • van der Schaaf R.J.
        • Arkenbout E.K.
        • AJ I.J.
        • et al.
        Bioresorbable scaffolds versus metallic stents in routine PCI.
        N Engl J Med. 2017; 376: 2319-2328
        • Ali Z.A.
        • Gao R.
        • Kimura T.
        • Onuma Y.
        • Kereiakes D.J.
        • Ellis S.G.
        • et al.
        Three-year outcomes with the absorb bioresorbable scaffold: Individual-patient-cata meta-analysis from the ABSORB Randomized Trials.
        Circulation. 2018; 137: 464-479
        • Ali Z.A.
        • Serruys P.W.
        • Kimura T.
        • Gao R.
        • Ellis S.G.
        • Kereiakes D.J.
        • et al.
        2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
        Lancet. 2017; 390: 760-772
        • Stone G.W.
        • Gao R.
        • Kimura T.
        • Kereiakes D.J.
        • Ellis S.G.
        • Onuma Y.
        • et al.
        1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis.
        Lancet. 2016; 387: 1277-1289
        • Australian Government Department of Health Therapeutic Goods Administration
        Absorb Bioresorbable Vascular Scaffold System Hazard Alert.
        TGA, 2017
        • Therapeutic Goods Administration
        Advice of Abbott Vascular Absorb Bioresorbable Vascular Scaffold.
        ([press release])2017
        • Stub D.
        • Lefkovits J.
        • Brennan A.L.
        • Dinh D.
        • Brien R.
        • Duffy S.J.
        • et al.
        The establishment of the Victorian Cardiac Outcomes Registry (VCOR): Monitoring and optimising outcomes for cardiac patients in Victoria.
        Heart Lung Circ. 2018; 27: 451-463
        • Cox N.
        • Brennan A.
        • Dinh D.
        • Brien R.
        • Cowie K.
        • Stub D.
        • et al.
        Implementing sustainable data collection for a cardiac outcomes registry in an Australian public hospital.
        Heart Lung Circ. 2018; 27: 464-468
        • Abbott Vascular
        Absorb GT1 TM Bioresorbable Vascular Scaffold (BVS) System Instructions for Use.
        • Cutlip D.E.
        • Windecker S.
        • Mehran R.
        • Boam A.
        • Cohen D.J.
        • van Es G.A.
        • et al.
        Clinical end points in coronary stent trials: a case for standardized definitions.
        Circulation. 2007; 115: 2344-2351
        • Harrell Jr., F.E.
        • Lee K.L.
        • Califf R.M.
        • Pryor D.B.
        • Rosati R.A.
        Regression modelling strategies for improved prognostic prediction.
        Stat Med. 1984; 3: 143-152
        • Sotomi Y.
        • Suwannasom P.
        • Serruys P.W.
        • Onuma Y.
        Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging.
        EuroIntervention. 2017; 12: 1747-1756
        • Raber L.
        • Brugaletta S.
        • Yamaji K.
        • O'Sullivan C.J.
        • Otsuki S.
        • Koppara T.
        • et al.
        Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings.
        J Am Coll Cardiol. 2015; 66: 1901-1914
        • Gori T.
        • Weissner M.
        • Gonner S.
        • Wendling F.
        • Ullrich H.
        • Ellis S.
        • et al.
        Characteristics, predictors, and mechanisms of thrombosis in coronary bioresorbable scaffolds: differences between early and late events.
        JACC Cardiovasc Interv. 2017; 10: 2363-2371
        • Puricel S.
        • Cuculi F.
        • Weissner M.
        • Schmermund A.
        • Jamshidi P.
        • Nyffenegger T.
        • et al.
        Bioresorbable coronary scaffold thrombosis: Multicenter comprehensive analysis of clinical presentation, mechanisms, and predictors.
        J Am Coll Cardiol. 2016; 67: 921-931
        • Collet C.
        • Asano T.
        • Miyazaki Y.
        • Tenekecioglu E.
        • Katagiri Y.
        • Sotomi Y.
        • et al.
        Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials.
        Eur Heart J. 2017; 38: 2559-2566
        • Windecker S.
        • Kolh P.
        • Alfonso F.
        • Collet J.P.
        • Cremer J.
        • Falk V.
        • et al.
        2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).
        Eur Heart J. 2014; 35: 2541-2619
        • McNeil J.J.
        • Evans S.M.
        • Johnson N.P.
        • Cameron P.A.
        Clinical-quality registries: their role in quality improvement.
        Med J Aust. 2010; 192: 244-245
        • Evans S.M.
        • Scott I.A.
        • Johnson N.P.
        • Cameron P.A.
        • McNeil J.J.
        Development of clinical-quality registries in Australia: the way forward.
        Med J Aust. 2011; 194: 360-363
        • Resnic F.S.
        • Majithia A.
        • Marinac-Dabic D.
        • Robbins S.
        • Ssemaganda H.
        • Hewitt K.
        • et al.
        Registry-based prospective, active surveillance of medical-device safety.
        N Engl J Med. 2017; 376: 526-535